Trial Profile
Combination therapy with a molecular target drug and iron chelator for the treatment of intractable hepatocellular carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Jul 2016
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Jul 2016 Status changed from not yet recruiting to discontinued.
- 17 Apr 2014 New trial record